1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 17 NOVEMBER 2014

Cancer Drug News 17 NOVEMBER 2014

  • November 2014
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Merck KGaA/Pfizer Alliance Is Strategic Move For Both In Immuno-Oncology
Industry Brief - First Patient Dosed In NeuVax+Herceptin Phase II Trial
Industry Brief - Pooled Data Show OS Benefit Of Halaven In HER2/Triple-Negative BC
Industry Brief - FDA Removes Full Clinical Hold On Imetelstat
Industry Brief - Daratumumab Additional Phase III Combination Study To Begin In Frontline MM
Industry Brief - FDA Approves Avastin Plus Chemotherapy For Platinum-Resistant Recurrent OC
Industry Brief - DSMB Recommends Continuation Of Masitinib Phase II Study In Advanced HCC
Industry Trend Analysis - Merck Places Confidence In Accurin Technology After Amgen's Exit
Industry Brief - Threshold's TH-302 Gains FDA Fast Track Designation For Advanced STS
Industry Brief - Advaxis Submits IND For Phase I/II Study Of ADXS-HPV And MedImmune's MEDI4736
Industry Brief - CASI Receives CFDA Approval For ENMD-2076 Phase II Trial In STS
Industry Brief - Blueprint Medicines Raises Funds In Series C Financing

Table Of Contents

Cancer Drug News 17 NOVEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.